KBY Biotech Indexv0.0.34
Search
← Pipeline|Elrarasimod

Elrarasimod

NDA/BLA
VES-1309
By Vesalius
Source: Trial-derived·Trials: 2
Modality
Radioligand
MOA
Anti-Tau
Target
TNFα
Pathway
Checkpoint
Asthma
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
~Jan 2019
→ ~Apr 2020
Phase 2
~Jul 2020
→ ~Oct 2021
Phase 3
~Jan 2022
→ ~Apr 2023
NDA/BLA
Jul 2023
→ Jan 2028
NDA/BLACurrent
NCT07670722
491 pts·Asthma
2025-04→2027-03·Recruiting
NCT03164605
2,870 pts·Asthma
2023-07→2028-01·Terminated
3,361 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-03-2012mo awayPh3 Readout· Asthma
2028-01-061.8y awayPh3 Readout· Asthma
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
NDA/BLA
Termina…
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-03-20 · 12mo away
Asthma
Ph3 Readout
2028-01-06 · 1.8y away
Asthma
RecruitingTerminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT07670722NDA/BLAAsthmaRecruiting491BodyWt
NCT03164605NDA/BLAAsthmaTerminated2870Mayo
Competitors (10)
DrugCompanyPhaseTargetMOA
RHH-7558RochePhase 1SGLT2Anti-Tau
NVS-5439NovartisPreclinicalBETAnti-Tau
ABB-3951AbbViePhase 2/3TNFαCDK2i
NVO-9630Novo NordiskPhase 2CD3Anti-Tau
GIL-6239Gilead SciencesPhase 2TNFαCGRPant
REG-2172RegeneronPhase 1/2PCSK9Anti-Tau
MRN-8225ModernaPreclinicalTNFαSGLT2i
SovanaritideArgenxPhase 3TNFαBETi
BGN-3305BeiGenePhase 2BCMAAnti-Tau
SovarasimodHalozymePhase 1/2WEE1Anti-Tau